Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Financial Challenges Amid Promising Cancer Treatments

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Financial Challenges Amid Promising Cancer Treatments

Add to Favorite
Added to Favorite


Earnings per share (EPS) of -$0.15681, slightly better than the estimated -$0.16, indicating a reduction in losses.
Revenue of $18.46 million, below the estimated $23.26 million, showing the company’s struggle to meet revenue expectations.
Despite financial challenges, a strong current ratio of 3.92 and a very low debt-to-equity ratio of 0.012 provide some financial stability.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is a commercial-stage biopharmaceutical company focused on developing innovative cancer treatments. The company specializes in radioimmunotherapy and antibody-based therapeutic products. Despite its promising focus, YMAB faces financial challenges, as highlighted in its recent earnings report for the third quarter of 2024.

On November 8, 2024, YMAB reported an earnings per share (EPS) of -$0.15681, slightly better than the estimated -$0.16. However, this was larger than the Zacks Consensus Estimate of a $0.14 loss per share. This result shows a slight improvement from the previous year’s loss of $0.18 per share, indicating some progress in reducing losses.

YMAB generated $18.46 million in revenue, falling short of the estimated $23.26 million. This shortfall highlights the company’s ongoing struggle to meet revenue expectations. Despite this, the company’s price-to-sales ratio of 8.20 suggests that investors are willing to pay $8.20 for every dollar of sales, indicating some confidence in its future potential.

The company’s financial metrics reveal challenges in profitability. With a negative price-to-earnings (P/E) ratio of -29.08 and a negative earnings yield of -3.44%, YMAB is currently not profitable. The enterprise value to operating cash flow ratio is also negative at -28.61, reflecting difficulties in generating positive cash flow from operations.

Despite these challenges, YMAB maintains a strong current ratio of 3.92, indicating a solid ability to cover short-term liabilities with short-term assets. Additionally, the debt-to-equity ratio is very low at 0.012, suggesting minimal debt compared to equity. These factors provide some financial stability as the company continues to navigate its path toward profitability.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Wheaton Precious Metals Corp. (NYSE:WPM) Financial Overview

Earnings Per Share (EPS) for Q3 2024 stood at...

NRG Energy, Inc. (NYSE:NRG) Stock Price Target Shows Positive Trend

The consensus price target for NRG Energy, Inc. (NYSE:NRG)...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Overview

The consensus price target for Xeris Biopharma's stock has...